Selvigaltin (GB1211), an orally available small molecule galectin-3 inhibitor made being a treatment method for liver fibrosis and cirrhosis, was evaluated to evaluate the effect of hepatic impairment on its pharmacokinetics and basic safety to deal with regulatory demands. Table four Statistical assessment of dose proportionality with the pharmacokinetic parameters https://selvigaltin-galectin-3-in02468.blog2news.com/39827477/1978336-95-6-for-dummies